Atherosclerosis is a lipid-driven disease of the artery characterized by chronic non-resolving inflammation. Despite availability of excellent lipid-lowering therapies, atherosclerosis remains the leading cause of disability and death globally. The demonstration that suppressing inflammation prevents the adverse clinical manifestations of atherosclerosis in recent clinical trials has led to heightened interest in anti-inflammatory therapies. In this review, we briefly highlight some key anti-inflammatory and pro-resolution pathways, which could be targeted to modulate pathogenesis and stall atherosclerosis progression. We also highlight key challenges that must be overcome to turn the concept of inflammation targeting therapies into clinical reality for atherosclerotic heart disease.

动脉粥样硬化是一种由脂质驱动的动脉疾病，其特征是慢性非消退性炎症。尽管有出色的降脂疗法可供使用，但动脉粥样硬化仍然是全球残疾和死亡的主要原因。在最近的临床试验中，抑制炎症可以防止动脉粥样硬化的不良临床表现，这引起了人们对抗炎疗法的兴趣。在这篇综述中，我们简要强调了一些关键的抗炎和促消退途径，这些途径可用于调节发病机制和延缓动脉粥样硬化的进展。我们还强调了必须克服的关键挑战，才能将炎症靶向疗法的概念转变为动脉粥样硬化性心脏病的临床现实。